|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 2 | The influence of behavioural and organisational characteristics on the success of international strategic alliances 显示文摘 | Kauser S Shaw V | 2004 | International Marketing Review2004，21，1： | 1 |
| 3 | Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA 显示文摘 | JUDGE AD SOOD V SHAW JR | 2005 | Nat Biotechnol2005，23，4： | 1 |
| 4 | A meta-analysis of strawberry yield response to replant soil fumigation with combination of methyl bromide-chloropicrin and from alternative systems显示文摘 | SHAW D V LARSON K D | 1999 | Hortscience1999，34，5： | 1 |
| 5 | Clinical Paediatric Dietetics显示文摘 | Shaw V Lawson M | | 0，，： | 1 |
| 6 | Pectenetoxins--an issue for public health:a review of their comparative toxicology and metabolism显示文摘 | Burgess V Shaw G | 2001 | Environlnt2001，271，： | 1 |
| 7 | Pectenotoxinsan issue for public health:a review of their comparative toxicology and metabolism显示文摘 | Burgess v Shaw g | 2001 | Environ Int2001，27，4： | 1 |
| 8 | Hyper-X: Foundation for future hypersonic launch vehicles显示文摘 | McClinton C R Rausch V L Shaw R J | 2005 | Acta Astronautica2005，57，： | 1 |
| 9 | Surface and subsur- face stress evaluation in case-carburised steel using high and low frequency magnetic barkhausen emission meas- urements显示文摘 | Moorthy V Shaw B A Hopkins P | 2006 | Journal of Magnetism and Magnetic Materi- als2006，299，： | 1 |
| 10 | Minireview: tri-chosanthin-a protein with multiple pharmacologicalproperties 显示文摘 | Shaw PC Chan WL Yeung H\V | 1994 | Life Sci1994，55，4： | 1 |
| 11 | 查看详情显示文摘 | Haynam C A Wegner P J Auerbach J M Bowers M W Dixit S N Erbert G V Heestand G M Henesian M A Hermann M R Jancaitis K S Manes K R Marshall C D Mehta N C Menapace J Moses E Murray J R Nostrand M C Orth C D Patterson R SacksR A Shaw M J Spaeth M Sutton S B W | | 0，，： | 1 |
| 12 | Chloramphenicol aeetyltransferase:enzymology and-molecular biology 显示文摘 | SHAW W V | 2008 | CRC Crit Rev Biochem2008，14，： | 1 |
| 13 | Mortality after emergent percutaneous coro- nary intervention in cardiogenic shock secondary to acute myo- cardial infarction and usefulness of a mortality prediction model 显示文摘 | Klein L W Shaw R E Krone R J Brindis R G Anderson H V Block P C | 2005 | Am J Cardiol2005，96，： | 1 |
| 14 | Estimation of outcrossing rate in Douglas-fir using isozyme markers显示文摘 | Shaw D V Allard R W | | 0，，： | 1 |
| 15 | Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: evidence from the NCDR(?)显示文摘 | Lichtman J H Wang Y Jones S B Leifheit-Limson E C Shaw L J Vaccarino V | 2014 | Am Heart J2014，167，： | 1 |
| 16 | Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates 显示文摘 | Lin YP Shaw M Gregory V | 2000 | Proc Natl Acad Sci U S A2000，97，17： | 1 |
| 17 | Flood risk management for the RUA of Hanoi:Importance of community perception of catastrophic flood risk in disaster risk planning显示文摘 | Hung H V Shaw R Kobayashi M | 2007 | Disaster Prevention and Management2007，16，2： | 1 |
| 18 | The role of wheel-work deflection in grinding operations 显示文摘 | KUMAR K V SHAW M C | 1981 | ASME1981，103，： | 1 |
| 19 | Avian-to-human transmission of H9N2 subtype influenza A viruses: Re- lationship between H9N2 and H5N1 human isolates 显示文摘 | Lin Y P Shaw M Gregory V | 2000 | PNAS2000，97，17： | 1 |
| 20 | Cloning of cDNA for the bovine IL-2 receptor(bovine Tac antigen)显示文摘 | WEINBERG A D SHAW J PAETKAU V | 1988 | Immunology1988，63，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员